Access, Access, Access: Unmet Needs in Multiple Myeloma
Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.
Transcript:
I think I’ve said it before a couple times: access, access, access. We need to figure out better ways to ensure every patient with myeloma has access to this new generation of cellular immunotherapies, either direct or indirect cellular immunotherapies. Right now, they’re grossly limited to academic centers with lots of [resources and] expertise because of the cytokine release syndrome and other aspects that make them a little more challenging to give [to patients], at least initially.
To effect real change in the community, or at least where multiple myeloma is being taken care of, we [have to] strive to translate these assets into more community-friendly therapeutics.
Transcript edited for clarity.
![“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma,\" according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
